{{Rsnum
|rsid=12329760
|Gene=TMPRSS2
|Chromosome=21
|position=41480570
|Orientation=plus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.2897
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=TMPRSS2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 57.1 | 40.2 | 2.7
| HCB | 37.5 | 46.3 | 16.2
| JPT | 39.8 | 43.4 | 16.8
| YRI | 55.8 | 40.8 | 3.4
| ASW | 54.4 | 38.6 | 7.0
| CHB | 37.5 | 46.3 | 16.2
| CHD | 36.7 | 49.5 | 13.8
| GIH | 73.3 | 23.8 | 3.0
| LWK | 51.8 | 40.0 | 8.2
| MEX | 69.0 | 27.6 | 3.4
| MKK | 41.9 | 48.4 | 9.7
| TSI | 66.7 | 26.5 | 6.9
| HapMapRevision=28
}}

[http://7thspace.com/headlines/289665/association_of_tmprss2_erg_gene_fusion_with_clinical_characteristics_and_outcomes_results_from_a_population_based_study_of_prostate_cancer.html news] rs12329760(T) associated with TMPRSS2-ERG fusion by translocation (p=0.05) and with multiple copies of the gene fusion (p=0.03) relevant to metastatic [[prostate cancer]].

{{PMID Auto
|PMID=18694509
|Title=Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
|OA=1
}}

{{GET Evidence
|gene=TMPRSS2
|aa_change=Val197Met
|aa_change_short=V197M
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12329760
|overall_frequency_n=2562
|overall_frequency_d=10758
|overall_frequency=0.238148
|n_genomes=2
|n_genomes_annotated=0
|n_haplomes=3
|n_articles=0
|n_articles_annotated=0
|nblosum100=0
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}